Transthyretin L55P Variant Monomers

Transthyretin L55P Variant Monomers

• Background: Transthyretin is a transport protein in the serum and cerebospinal fluid that carried the thyroid hormone Thyroxine and retinol-binding protein bound to retinol. TTR misfolding and aggregation is known to be associated with the amyloiddiseases SSA, FAP and FAC (1-5). TTR is also thought to have beneficial side effects, such as binding to beta-amyloid protein, preventing beta-amyloid from accumulating into the plaques associated with Alzheimer's Disease (6). The L55P variant TTR is distinct from the other variants in that the L55P tetramer can dissociate to the monomeric amyloidogenic intermediate and form fibril precursors (7).
• Description: Human Recombinant Transthyretin L55P Variant Protein Monomers
• Product Name Alternative: Amyloid polyneuropathy Protein Monomer, Amyloidosis I Protein Monomer, ATTR Protein Monomer, Carpal tunnel syndrome 1 Protein Monomer, CTS Protein Monomer, CTS1 Protein Monomer,= HEL111 Protein Monomer, HsT2651 Protein Monomer, PALB Protein Monomer, Prealbumin Protein Monomer, Prealbumin amyloidosis type I Protein Monomer, Prealbumin Thyroxine-binding Protein Monomer, TBPA Protein Monomer, Thyroxine binding prealbumin Protein Monomer, Transthyretin Protein Monomer, TTHY_HUMAN Protein Monomer,TTR Protein Monomer, TTR protein
• UNSPSC: 12352202
• Gene ID: 7276
• Swiss Prot: P02766
• Accession Number: NP_000362.1
• Cellular Locus: Cytoplasm | Extracellular exosome | Extracellular Region | Lysosome
• Host: E. coli
• Origin Species: Human
• Target: Transthyretin (TTR)
• Conjugation: No tag
• Sequence: MGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGEPHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE
• Applications: WB, SDS-PAGE, In vivo assay, In vitro assay
• Purification Method: Ion-exchange Purified
• Concentration: Lot/batch specific. See included datasheet.
• Purity: >95%
• Weight: 0.2
• Length: Full length
• Buffer: PBS pH 7.4
• Molecular Weight: 13.876 kDa
• Precautions: Not for use in humans. Not for use in diagnostics or therapeutics. For research use only.
• Additionnal Information: For corresponding PFFs, see catalog# SPR-464
• References & Citations: 1. Zeldenrust S.R., Benson M.D. (2010). Wiley. pp. 795–815. 2. Westermark P., Sletten K., Johansson B., Cornwell G.G. (1990). Proc. Natl. Acad. Sci. U.S.A. 87(7): 2843–5. 3. Andrade C. (1952). Brain. 75(3): 408–27. 4. Coelho T. (1996). Curr. Opin. Neurol. 9(5): 355–9. 5. Jacobson D.R, et. al. (1997). N. Engl. J. Med. 336(7): 466–73. 6. Li X. (2011). Mol Neurodegener. 6(1):79. 7. Lashuel H.A., Wurth C., Woo L., and Kelly J.W. (1999) Biochem. 38(41): 13560-13573.